Respiratory Research (May 2023)

The association of spirometric small airways obstruction with respiratory symptoms, cardiometabolic diseases, and quality of life: results from the Burden of Obstructive Lung Disease (BOLD) study

  • Ben Knox-Brown,
  • Jaymini Patel,
  • James Potts,
  • Rana Ahmed,
  • Althea Aquart-Stewart,
  • Cristina Barbara,
  • A. Sonia Buist,
  • Hamid Hacene Cherkaski,
  • Meriam Denguezli,
  • Mohammed Elbiaze,
  • Gregory E. Erhabor,
  • Frits M. E. Franssen,
  • Mohammed Al Ghobain,
  • Thorarinn Gislason,
  • Christer Janson,
  • Ali Kocabaş,
  • David Mannino,
  • Guy Marks,
  • Kevin Mortimer,
  • Asaad Ahmed Nafees,
  • Daniel Obaseki,
  • Stefanni Nonna M. Paraguas,
  • Li Cher Loh,
  • Abdul Rashid,
  • Sundeep Salvi,
  • Terence Seemungal,
  • Michael Studnicka,
  • Wan C. Tan,
  • Emiel F. M. Wouters,
  • Hazim Abozid,
  • Alexander Mueller,
  • Peter Burney,
  • Andre F. S. Amaral

DOI
https://doi.org/10.1186/s12931-023-02450-1
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Background Spirometric small airways obstruction (SAO) is common in the general population. Whether spirometric SAO is associated with respiratory symptoms, cardiometabolic diseases, and quality of life (QoL) is unknown. Methods Using data from the Burden of Obstructive Lung Disease study (N = 21,594), we defined spirometric SAO as the mean forced expiratory flow rate between 25 and 75% of the FVC (FEF25-75) less than the lower limit of normal (LLN) or the forced expiratory volume in 3 s to FVC ratio (FEV3/FVC) less than the LLN. We analysed data on respiratory symptoms, cardiometabolic diseases, and QoL collected using standardised questionnaires. We assessed the associations with spirometric SAO using multivariable regression models, and pooled site estimates using random effects meta-analysis. We conducted identical analyses for isolated spirometric SAO (i.e. with FEV1/FVC ≥ LLN). Results Almost a fifth of the participants had spirometric SAO (19% for FEF25-75; 17% for FEV3/FVC). Using FEF25-75, spirometric SAO was associated with dyspnoea (OR = 2.16, 95% CI 1.77–2.70), chronic cough (OR = 2.56, 95% CI 2.08–3.15), chronic phlegm (OR = 2.29, 95% CI 1.77–4.05), wheeze (OR = 2.87, 95% CI 2.50–3.40) and cardiovascular disease (OR = 1.30, 95% CI 1.11–1.52), but not hypertension or diabetes. Spirometric SAO was associated with worse physical and mental QoL. These associations were similar for FEV3/FVC. Isolated spirometric SAO (10% for FEF25-75; 6% for FEV3/FVC), was also associated with respiratory symptoms and cardiovascular disease. Conclusion Spirometric SAO is associated with respiratory symptoms, cardiovascular disease, and QoL. Consideration should be given to the measurement of FEF25-75 and FEV3/FVC, in addition to traditional spirometry parameters.

Keywords